Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumasiran in hyperoxalaemic patients on haemodialysis
2022-002681-32Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jan 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of lumasiran in Hyperoxalemia and end-stage kidney disease (ESKD), sponsored by Charité – Universitätsmedizin Berlin. Started Jan 2023; status: completed.
02
Drugs
lumasiran
03
Conditions
Hyperoxalemiaend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2022-002681-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002681-32.